Key Insights on Gross Profit: Zoetis Inc. vs BioCryst Pharmaceuticals, Inc.

Zoetis vs BioCryst: A Decade of Gross Profit Growth

__timestampBioCryst Pharmaceuticals, Inc.Zoetis Inc.
Wednesday, January 1, 2014134860003068000000
Thursday, January 1, 2015463610003027000000
Friday, January 1, 2016236540003222000000
Sunday, January 1, 2017234840003532000000
Monday, January 1, 2018201820003914000000
Tuesday, January 1, 2019447340004268000000
Wednesday, January 1, 2020161360004618000000
Friday, January 1, 20211499060005473000000
Saturday, January 1, 20222642330005626000000
Sunday, January 1, 20233267510005834000000
Monday, January 1, 20246537000000
Loading chart...

Data in motion

A Tale of Two Companies: Zoetis Inc. vs BioCryst Pharmaceuticals, Inc.

In the world of pharmaceuticals, the financial health of a company is often reflected in its gross profit. Over the past decade, Zoetis Inc. and BioCryst Pharmaceuticals, Inc. have shown contrasting trajectories. Zoetis, a leader in animal health, has consistently demonstrated robust growth, with its gross profit increasing by approximately 90% from 2014 to 2023. In contrast, BioCryst, known for its innovative treatments for rare diseases, has seen a more volatile journey, with a staggering 2,300% increase in gross profit over the same period, albeit from a much smaller base.

Key Insights

  • Zoetis Inc.: Steady growth, peaking at $5.8 billion in 2023.
  • BioCryst Pharmaceuticals, Inc.: Rapid growth, reaching $327 million in 2023.

These trends highlight the diverse strategies and market positions of these two pharmaceutical giants.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025